Ovarian Cancer Translational Program
SPORE in Ovarian Cancer
Testing a new fallopian-tube/ovary brush to find early changes and new drug combinations to better treat advanced or ARID1A-mutant ovarian cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11194300 on NIH RePORTER |
What this research studies
This program moves lab discoveries into care by combining three linked projects and shared research cores. One project is developing a brush method to sample fallopian tubes and ovaries to find precursor lesions and study their molecular features. Another project is using cyclin E1 to guide treatment with a WEE1 inhibitor and combinations with an ATR inhibitor to overcome resistance. A third project targets DNA-repair weaknesses in ARID1A-mutant ovarian cancers with drug combinations such as temozolomide.
Who could benefit from this research
Good fit: Ideal candidates include people at risk for ovarian cancer or with suspected fallopian-tube/ovarian precursor lesions, and patients with advanced or recurrent ovarian cancer—particularly those whose tumors have cyclin E1 elevation or ARID1A mutations.
Not a fit: People without ovarian disease or whose tumors lack the specific biomarkers targeted by the projects (for example no cyclin E1 signal or no ARID1A mutation) may not receive direct benefit from these specific approaches.
Why it matters
Potential benefit: If successful, this work could enable earlier detection of precursor lesions and offer more effective, biomarker-guided drug combinations for recurrent or ARID1A-mutant ovarian cancer.
How similar studies have performed: Early lab and some clinical work supports WEE1 and ATR targeting and exploiting DNA-repair vulnerabilities in certain tumors, but the fallopian-tube brush detection approach and the exact drug combinations proposed remain partly unproven in ovarian cancer.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Shih, Ie-Ming — Johns Hopkins University
- Study coordinator: Shih, Ie-Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.